ScholarWorks@Hanyang University: Lee, Hyun

Detailed Information

Lee, Hyun (이현)

COLLEGE OF MEDICINE (DEPARTMENT OF INTERNAL MEDICINE)

Research Area

Tel 02-2290-8350
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

bronchiectasis:15||chronic obstructive pulmonary disease:12||Bronchiectasis:11||epidemiology:10||Asthma:9||asthma:7||tuberculosis:7||mortality:6||COPD:6||nontuberculous mycobacteria:6||treatment outcome:6||diagnosis:6||Mortality:5||treatment:5||Mycobacterium abscessus:5||lung cancer:4||prevalence:4||Mycobacterium avium complex:4||Nontuberculous mycobacteria:4||risk factor:4||Lung cancer:4||severity:4||influenza:3||COVID19:3||Pulmonary tuberculosis:3||prognosis:3||Spirometry:3||smoking:3||Tuberculosis:3||vaccination:3||surgery:3||airflow limitation:3||interstitial lung disease:3||risk factors:3||quality of life:3||therapeutics:2||nonsmall cell lung cancer (NSCLC):2||nontuberculous mycobacteria:2||forced vital capacity (FVC):2||Diagnosis:2||obesity:2||hand grip strength:2||Chronic obstructive pulmonary disease (COPD):2||Neoplasm staging:2||Nonsmall cell lung cancer:2||Validation:2||idiopathic pulmonary fibrosis:2||physical activity:2||Nonsmall cell lung carcinoma:2||IgG:2||pneumonia:2||population:2||cohort study:2||IgG subclass deficiency:2||Intensive care unit:2||Interstitial lung disease:2||acute exacerbation:2||Rifabutin:2||corticosteroid:2||cough:2||Epidemiology:2||adverse reactions:2||Brain metastasis:2||diabetes mellitus:2||disease burden:2||airway obstruction:2||drug resistance:2||macrolides:2||Severe asthma:2||Korea:2||Chronic Obstructive:2||biologics:2||exacerbation:2||sixminute walk test:2||spirometry:2||sputum microbiology:2||Comorbidity:2||body mass index:2||steroids:2||Survey:2||survival:2||NTM:2||Pulmonary Disease:2||Lung function:1||Lung neoplasms:1||Lymphatic invasion:1||M. abscessus:1||Macrolides:1||Menarche:1||Menopause:1||Metabolic syndrome:1||Midazolam:1||Multidrugresistant tuberculosis:1||Mycobacterial disease:1||Mycobacterium chimaera:1||Mycobacterium intracellulare:1||Mycobacterium massiliense:1||Mycobacterium tuberculosis:1||NAT2 genotype:1||National Health and Nutrition Examination Survey (NHANES):1||National Health and Nutritional Examination Survey:1||Natural history:1||Nontuberculosis mycobacterial (NTM) infection:1||Nutrition:1||Operator factor:1||Oral Health:1||Patient reported outcome:1||Patient safety:1||PatientReported Outcome Measurement Information System 29 Profile V2.1 (KPROMIS29 V2.1):1||Peak expiratory flow rate:1||Pharmacotherapy:1||Physical therapy:1||Physical therapy modalities:1||Pleural recurrence:1||Postoperative pulmonary complications:1||Prevalence:1||Preventive Health Services:1||Propensity Score:1||Propofol:1||Pulmonary cryptococcosis (PC):1||Pulmonary function:1||Pulmonary tuberculosis (pulmonary TB):1||QuantiFERONTB Gold:1||Race:1||Real world:1||Registries:1||Remifentanil:1||Reproductive period:1||Respiratory Function Tests:1||Rheumatoid arthritis:1||Risk Factors:1||Risk factors:1||SABA:1||Safety:1||Scrub Typhus:1||Serum and radiologic biomarker:1||Sex hormone:1||Sinusitis:1||Smokers:1||Smoking cessation:1||Squamous cell carcinoma:1||Surgery:1||Surveys:1||Therapeutics:1||Tissue Organ Procurement:1||Transthoracic needle biopsy:1||Treatment:1||Treatment outcome:1||Treatment outcomes:1||Underweight:1||Visceral pleural invasion:1||Vital signs:1||Vitamin:1||Young Adult:1||Young adults:1||acidfast bacilli:1||acute respiratory failure:1||adverse reaction:1||age:1||air pollution:1||amikacin:1||anemia:1||antibody:1||antifungal:1||artificial intelligence:1||asthma exacerbation:1||asthmaCOPD overlap:1||azithromycin:1||biological products:1||biomarker:1||bronchial asthma:1||bronchial disease:1||bronchial hyperresponsiveness:1||bronchicctasis:1||bronchiectasis health questionnaire:1||bronchodilator agents:1||bronchodilator effect:1||cancer:1||cardiovascular disease:1||cavitation:1||chronic lower airway disease:1||chronic obstructive pulmonary disease (COPD):1||clinical epidemiology:1||clofazimine:1||cohort:1||comorbidity:1||complications:1||consensus:1||cooking:1||coronavirus disease 2019:1||crosssectional studies:1||culture media:1||cyclooxygenase:1||death:1||disease exacerbation:1||disease management:1||disease severity:1||dyslipidemia:1||early mobilization:1||ecological model:1||endobronchial ultrasoundguided transbronchial needle aspiration:1||energy ratio:1||environmental pollution:1||eosinophil:1||eosinophils:1||estrogen:1||ethics:1||expert opinion:1||extracorporeal membrane oxygenation:1||extranodal marginal Bcell lymphoma:1||female:1||fishes:1||fluoroquinolones:1||forced expiratory flow between 25% and 75% of vital capacity:1||gastrooesophageal reflux disease:1||gastroesophageal reflux:1||gastrointestinal tract:1||hand hygiene:1||health care:1||health care workers:1||health economics:1||healthcare workers:1||hormone replacement therapy:1||indoor:1||infection control:1||influenza vaccination:1||inhalation:1||insulinlike growth factorI:1||insulinlike growth factorbinding protein3:1||intensive care units:1||interleukin1 beta:1||internal medicine:1||invasive fungal disease:1||ischemic heart disease:1||ischemic stroke:1||kaempferol:1||lipocalin2:1||lipoprotein, HDL:1||long shortterm memory:1||loudness:1||lung disease:1||lung function tests:1||lung neoplasm:1||lung neoplasms:1||lung recovery:1||lungm neoplasm:1||machinelearning:1||management:1||mannitol:1||matrix metalloproteinases:1||maximal midexpiratory flow:1||meat:1||medical cost:1||metaanalysis:1||microscopy:1||military facilities:1||morbidity:1||moxifloxacin:1||mucormycosis:1||myocardial infarction:1||national immunization program:1||neoplasm staging:1||nephrotoxicity:1||neversmoker:1||nontuberculosis mycobacterium:1||nutritional status:1||obstructive lung diseases:1||ofloxacin:1||older population:1||oscillating positive expiratory pressure:1||ototoxicity:1||outcome:1||particulate matter:1||peak expiratory flow:1||periostin:1||pharmacogenomics:1||phenotype:1||physiotherapy:1||pollution:1||polymerase chain reaction:1||population base study:1||positron emission tomography:1||postoperative complications:1||prescription:1||prescription patterns:1||prolonged maintenance:1||prostaglandin E2:1||public health:1||pulmonary:1||pulmonary complication:1||pulmonary embolism:1||pulmonary fibrosis:1||pulmonary surgical procedures:1||pulmonary tuberculosis:1||questionnaire:1||racial difference:1||recurrence:1||registries:1||registry:1||reliability:1||reproductive period:1||respiratory function test:1||respiratory tract infection:1||retrospective cohort:1||rheumatic diseases (RDs):1||rheumatoid arthritis:1||rheumatoid arthritis (RA):1||rinse fluid:1||risk:1||sarcopenia:1||secular trend:1||sedentary behavior:1||severe asthma:1||sex:1||small cell lung cancer (SCLC):1||sputum volume:1||stage IA lung adenocarcinoma:1||standards:1||surveys and questionnaires:1||survivors:1||symptom burden:1||symptom exacerbations:1||thoracic surgery:1||thoracic surgical procedures:1||timed upandgo test:1||total lung capacity:1||triglycerides:1||tuberculosis (TB):1||tuberculosisdestroyed lung:1||tuberculous lymphadenitis:1||twomonth culture:1||ultralong acting beta(2)agonist (LABA):1||ultralongacting muscarinic antagonist (LAMA):1||uric acid:1||vaccine:1||validity:1||venous thromboembolism:1||walk test:1||6minwalk test (6MWT):1||wheezing:1||AMK:1||Actinomycosis:1||Acute:1||Adenocarcinoma:1||Airflow Limitation:1||Airflow obstruction (AO):1||Allergic rhinitis:1||Allergy:1||Analgosedation:1||Anaplastic lymphoma kinase (ALK):1||Asia:1||Association factors:1||Atopic dermatitis:1||Biological products:1||Biopsy:1||Body mass index:1||Brain Death:1||Brain atrophy:1||Bronchiectasis Health Questionnaire:1||Bronchoscopy:1||COPD overlap:1||COVID 19:1||COVID19 infection:1||Cancer screening:1||Candida:1||Cardiovascular diseases:1||Cavity:1||Cerebral small vessel disease:1||ChAdOx1 nCoV19 vaccine:1||Cholecystitis:1||Chronic Obstructive Pulmonary Disease:1||Chronic obstructive pulmonary disease:1||Chronic pulmonary aspergillosis:1||Chronic pulmonary diseases (CPDs):1||Clinical characteristics:1||Cohort:1||Cohort Studies:1||Complication:1||Complications:1||Computed tomography:1||Consensus Guideline:1||Continuous renal replacement therapy:1||Cough:1||DMFT Index:1||Demography:1||Disease Management:1||Disease management:1||Disease prevention:1||Drug resistance:1||Drug susceptibility testing:1||ECMO:1||EUSNA):1||Elderly patients:1||Emphysema:1||Endosonography with needle aspiration (EBUS:1||Epidemiologic factors:1||Ethnicity:1||Etiology:1||Exercise:1||Exercise therapy:1||Extensively drugresistant tuberculosis:1||Extracorporeal Membrane Oxygenation:1||Extracorporeal membrane oxygenation:1||False negative rate:1||Female:1||GERD (gastroesophageal reflux disease):1||Genetic alterations:1||Guideline:1||Histology:1||ICU:1||IL4:1||IL5:1||INH regimen:1||Idiopathic:1||IgE:1||Invasive fungal infection:1||Isoniazid resistance:1||Itraconazole:1||Kartagener syndrome:1||LTBI:1||Liquid medium:1||Lung Diseases, Obstructive:1||

STATISTICS: Total View :5,044,142; Today View :5,785

RSS_1.0 RSS_2.0 ATOM_1.0

222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE